Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologyColorado Rocky Mountain HP Voyxact Prior Auth | Op…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy N/A

    Voyxact (sibeprenlimab-szsl) — Prior authorization / medical necessity for primary IgA nephropathy

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical necessity criteria for Voyxact to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid progression; applies to Colorado Rocky Mountain Health Plans pharmacy benefit decisions.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyVoyxact (sibeprenlimab-szsl) prior authorization / medical necessity for primary IgAN
    Policy CodePolicy N/A
    Change TypeNew programremoved SGLT2 steprevised steroid trial language
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of renal biopsy-confirmed primary IgAN, baseline eGFR ≥30, evidence of proteinuria reduction for reauthorization, and nephrologist involvement.
    SourceLink
    POLICY UPDATE CHANGES

    Voyxact (sibeprenlimab-szsl) is included with prior authorization/medical necessity criteria.

    SGLT2 step was removed from the program requirements.

    Updated language in the steroid trial requirement.

    12 monthsauthorization duration
    ≥30min eGFR
    adult IgAN

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    indicated population
    nephrologistspecialist required

    Coverage Criteria for Voyxact (sibeprenlimab-szsl)

    Initial Authorization

    Covered when ALL of the following are met:

    Initial Authorization for Voyxact: Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by renal biopsy.
    Patient is at risk of rapid disease progression.
    Used to reduce proteinuria.
    Estimated glomerular filtration rate (eGFR) >= 30 mL/min/1.73 m2.eGFR >= 30 mL/min/1.73 m2
    Either: (1) patient is on a stabilized dose and receiving concomitant therapy with a maximally tolerated ACE inhibitor or an ARB, OR (2) patient has a contraindication or intolerance to ACE inhibitors and ARBs.

    Stabilized dose requirement may be waived if contraindication or intolerance documented.

    History of failure after a 30-day trial, contraindication, or intolerance to a glucocorticoid (e.g., budesonide, methylprednisolone, prednisone).

    30-day steroid trial requirement.

    Prescribed by or in consultation with a nephrologist.

    Reauthorization

    Covered when ALL of the following are met:

    Reauthorization for Voyxact: Documentation of positive clinical response demonstrated by a reduction in proteinuria.documented reduction in proteinuria

    Authorization issued for 12 months if response shown.

    Prior authorization is required for Voyxact and approvals are time-limited; initial and reauthorization approvals are issued for 12 months contingent on meeting the documentation and response requirements.

    For reauthorization, documentation must demonstrate a positive clinical response shown by a reduction in proteinuria and continued fulfillment of eligibility criteria.

    Therapy is covered only when the diagnosis of primary IgA nephropathy is confirmed by renal biopsy. Baseline renal function must meet the program threshold of eGFR ≥ 30 mL/min/1.73 m2 to be eligible for treatment.

    Voyxact is intended to reduce proteinuria in patients at risk of rapid progression and must be prescribed either while the patient is on a stabilized, maximally tolerated ACE inhibitor or ARB (examples: captopril, enalapril, candesartan, valsartan) or when there is a documented contraindication or intolerance to ACE inhibitors/ARBs.

    Patients must have a history of failure, contraindication, or intolerance to a glucocorticoid after a 30-day trial (examples include budesonide, methylprednisolone, prednisone) unless glucocorticoids are contraindicated or not tolerated.

    Voyxact must be prescribed by or in consultation with a nephrologist. Failure to document biopsy confirmation, risk of rapid progression, baseline eGFR meeting the threshold, stabilized concomitant ACEi/ARB therapy (or contraindication), a completed 30-day steroid trial (or documented contraindication/intolerance), or nephrology involvement may render the request not medically necessary.

    Referenced Coding and Key Clinical Thresholds

    Referenced coding sourcesmixed
    No codes listed
    eGFR — eligibility threshold
    eGFR threshold>= 30 mL/min/1.73 m2
    ContextMinimum renal function required for initial authorization
    Relation to eligibilityeGFR below 30 mL/min/1.73 m2 may trigger denial

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required; 12‑month approvals

    Prior authorization is required for Voyxact. Initial approvals are issued for 12 months; reauthorizations are also issued for 12 months and require documentation of a positive clinical response (reduction in proteinuria).

    Step Therapy

    Concomitant ACEi/ARB required (or documented contraindication)

    Patient must be on a stabilized dose and receiving concomitant therapy with a maximally tolerated ACE inhibitor or ARB, unless the patient has a documented contraindication or intolerance to ACE inhibitors and ARBs.

    • Examples of ACE inhibitors: captopril, enalapril (document maximally tolerated dose).
    • Examples of ARBs: candesartan, valsartan (document maximally tolerated dose).
    • If contraindicated or intolerant to both ACEi and ARB, document the contraindication/intolerance.

    Definitions and Operational Terms

    Stabilized dose — operational note
    DefinitionUse of a consistent, maximally tolerated dose of an ACE inhibitor or ARB prior to initiating Voyxact, unless contraindicated or not tolerated.
    PurposeDemonstrates patient is receiving optimized renin‑angiotensin blockade before Voyxact initiation
    DocumentationProvider must document stabilized dose or record a contraindication/intolerance to ACEi/ARB
    ExamplesACE inhibitors (e.g., captopril, enalapril) or ARBs (e.g., candesartan, valsartan)

    Background

    The indication for Voyxact is limited to adults with primary immunoglobulin A nephropathy (primary IgAN) who are at risk of rapid disease progression. The long-term impact of Voyxact on slowing kidney function decline has not been established; continued approval may depend on confirmatory clinical trial evidence demonstrating clinical benefit. (See Initial Authorization and Reauthorization criteria for permitted uses and duration.)

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyVoyxact (sibeprenlimab-szsl) prior authorization / medical necessity for primary IgAN
    Policy CodePolicy N/A
    Change TypeNew programremoved SGLT2 steprevised steroid trial language
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of renal biopsy-confirmed primary IgAN, baseline eGFR ≥30, evidence of proteinuria reduction for reauthorization, and nephrologist involvement.
    SourceLink
    On This Page
    Coverage Criteria for Voyxact (sibeprenlimab-szsl)Referenced Coding and Key Clinical ThresholdsProvider Actions, Prior Authorization, and DocumentationDefinitions and Operational TermsBackground
    Documentation Required

    Documentation required (initial and reauthorization)

    Required documentation must be submitted with the prior authorization request and for reauthorization.

    • Renal biopsy confirming primary IgA nephropathy.
    • Evidence the patient is at risk of rapid disease progression.
    • Baseline eGFR showing ≥ 30 mL/min/1.73 m2.
    • Documentation of concomitant stabilized ACE inhibitor or ARB use, or documentation of contraindication/intolerance.
    • Documentation of a 30‑day glucocorticoid trial failure, or contraindication/intolerance to glucocorticoids.
    • Prescription by or documentation of consultation with a nephrologist.
    • For reauthorization: documentation of reduction in proteinuria demonstrating positive clinical response.
    Denial Risk

    Triggers for denial

    The following conditions may trigger denial of coverage for Voyxact.

    • No renal biopsy documentation confirming primary IgA nephropathy.
    • No documentation that the patient is at risk of rapid disease progression.
    • Baseline eGFR < 30 mL/min/1.73 m2.
    • No documentation of stabilized concomitant ACE inhibitor or ARB therapy and no documented contraindication/intolerance.
    • No documentation of a 30‑day glucocorticoid trial failure or documented contraindication/intolerance.
    • Prescription not by or not in consultation with a nephrologist.